ANI launches prazosin capsules

ANI is introducing prazosin HCl capsules in dosage strengths of 1 mg and 2 mg.

"Launch of Prazosin HCl is ANI’s fourteenth re-commercialization of a previously discontinued abbreviated new drug application product,” said Nikhil Lalwani, ANI president and CEO. “The launch underscores our capabilities and commitment to capture the full value of our product portfolio and manufacturing capabilities.”

Prazosin HCl Capsules are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.

Prazosin capsules had a market value of approximately $46.2 million, according to IQVIA.